About Dobataf-3 Tablet
Dobataf-3 Tablet 30s is an antiretroviral medicine used to treat HIV-1 infection in adults and children above 12 years of age weighing at least 40 kg. It contains dolutegravir, emtricitabine, and tenofovir alafenamide, which work together to block the replication of the HIV virus, helping lower the viral load, protect the immune system, and reduce the risk of HIV-related complications. The medicine should be taken exactly as prescribed, and some people may experience mild side effects such as headache, nausea, tiredness, or difficulty sleeping, which usually improve over time. Patients should consult their doctor if they are pregnant or planning pregnancy, avoid breastfeeding and alcohol during treatment, and continue practising safe sex, as the medicine does not prevent transmission of HIV to others.
Powerful Combination Therapy for HIV-1Dobataf-3 Tablet harnesses the synergistic effects of Dolutegravir, Emtricitabine, and Tenofovir Alafenamide to target HIV-1. By inhibiting viral replication through multiple mechanisms, it helps lower the viral load, improves immune response, and reduces the risk of HIV-related complications. The triple combination therapy is recommended in clinical settings for optimal treatment efficacy.
Safe and Convenient Dosage FormDesigned as a user-friendly oral tablet, Dobataf-3 ensures ease of administration for patients. Each package contains 30 tablets, aligning with standard monthly regimens. Proper adherence to the prescribed dosage, as directed by a healthcare professional, maximizes therapeutic success and improves the patient's quality of life.
Quality and Storage AssuranceManufactured in India complying with pharmaceutical standards, Dobataf-3 maintains its efficacy by adhering to recommended storage conditions. Keep the tablets in a cool, dry place away from sunlight to ensure they remain potent until their expiration date in 2028. Reliable packaging makes it suitable for hospital, clinical, and export markets.
FAQ's of Dobataf-3 Tablet:
Q: How should Dobataf-3 Tablet be taken for optimal effectiveness?
A: Dobataf-3 should be taken precisely as directed by your healthcare provider, typically once daily with or without food. Regular adherence to the dosing schedule is crucial for controlling HIV-1 infection and optimizing treatment outcomes.
Q: What conditions does Dobataf-3 Tablet treat?
A: Dobataf-3 Tablet is indicated for the management of HIV-1 infection. It helps suppress the virus, supports immune function, and reduces the risk of HIV-related complications.
Q: Where should Dobataf-3 Tablets be stored to maintain their quality?
A: Store Dobataf-3 Tablets in a cool and dry place, away from sunlight and moisture. Proper storage preserves the medication's effectiveness until the listed expiration date in 2028.
Q: What is the benefit of using a combination formulation like Dobataf-3?
A: The combination of Dolutegravir, Emtricitabine, and Tenofovir Alafenamide works through complementary mechanisms, enhancing viral suppression, reducing pill burden, and minimizing the risk of resistance compared to single-drug regimens.
Q: When does Dobataf-3 Tablet expire, and how can I check this?
A: Dobataf-3 Tablet has an expiration date of 2028. The exact date can be found on the product packaging; always check before use to ensure safety and efficacy.
Q: How is Dobataf-3 supplied and who can use it?
A: Dobataf-3 is packaged in boxes of 30 tablets and is intended for supply to hospitals, clinics, and through regulated export channels. It is prescribed for adults diagnosed with HIV-1 by healthcare professionals.
Q: What is the process of obtaining Dobataf-3 Tablet in India?
A: Dobataf-3 can be obtained by prescription through authorized medical suppliers, hospitals, or clinics in India. Exporters, suppliers, and traders can source the product from licensed pharmaceutical distributors.